Membrane-bound TRAIL-armoring augments CAR-T cells in mesothelin-positive solid malignancies

Our plain-English summary of Membrane-bound TRAIL-armoring augments CAR-T cells in mesothelin-positive solid malignancies, by A. Volpe, J. Zurita, L. Shenker, et al (Journal for Immunotherapy of Cancer, 2026).

The study

• Authors: A. Volpe, J. Zurita, L. Shenker, M.M. Mane, P.S. Adusumilli, A. Aleshin, D. Rozanov, V. Ponomarev
• Journal: Journal for Immunotherapy of Cancer
• Published: 2026;14(5)
• Read it: PubMed · Publisher · Free full text

Abstract

Background: Mesothelin (MSLN)-targeted chimeric antigen receptor (CAR)-T cell therapy shows an effective and long-lasting response in high MSLN-expressing tumors, but fails to treat tumors with heterogeneous levels of antigen expression. Here we describe an innovative approach where a stable tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) chimera, referred to as membrane-bound (MB)-TRAIL, is expressed on the cell surface of MSLN-specific (M28z) CAR-T cells. This potentiates their overall anticancer activity by overcoming heterogeneous antigen expression in tumor lesions.

Methods: We engineered MB-TRAIL-armored MSLN-directed M28z CAR-T cells and assessed their in vitro toxicity using flow cytometry against tumor target cells with heterogeneous MSLN expression. Triple-multiplex bioluminescence imaging using three different reporter genes enabled simultaneous in vivo non-invasive and longitudinal assessment of CAR-T cell dynamics, as well as MSLN+ and MSLN- tumor responses in xenograft models of MSTO-211H pleural mesothelioma (PM) and A549 non-small cell-lung cancer (NSCLC) with heterogeneous antigen expression. We further tested the therapeutic benefit of combining MB-TRAIL-armored CAR-T cells with the clinically used TRAIL sensitizer, doxorubicin, in an A549 xenograft model.

Results: MB-TRAIL M28z CAR-T cell therapy provides pro-apoptotic stimuli to both MSLN+ and MSLN- tumors, significantly improving survival in models of MSTO-211H PM and A549 NSCLC with heterogeneous antigen expression. We also demonstrated that our treatment confers sustained protection against metastatic spread in the MSTO-211H model, whereas doxorubicin overcomes TRAIL resistance rendering the A549 model more susceptible to MB-TRAIL M28z CAR-T cell therapy and reducing metastatic growth.

Conclusions: Our strategy confers superior antitumor efficacy relative to clinically trialed M28z CAR-T cells by directly targeting heterogeneous tumor antigen expression. These results constitute the foundation for developing a new class of clinically translatable TRAIL-armored CAR-T cell immunotherapies for the treatment of a wider range of malignancies.

© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.

In plain English

This was a laboratory and mouse study, not a study of people with asbestos-related disease. The authors built mesothelin (MSLN)-targeted M28z CAR-T cells from healthy donor T cells and additionally engineered them to carry a stabilised, membrane-bound TRAIL chimera (MB-TRAIL). They tested these cells against MSLN-positive and MSLN-negative MSTO-211H pleural mesothelioma and A549 non-small cell lung cancer cells, and in mice bearing mixed MSLN-positive/MSLN-negative tumours, tracked by three-reporter bioluminescence imaging. In culture at a 1:2 target-to-effector ratio, MB-TRAIL M28z cells killed more MSLN-positive cells at 24 hours than unarmoured M28z cells (58.5% vs 22.13% for MSTO-211, p=0.0019; 41.15% vs 14.84% for A549, p<0.0001), and unlike M28z cells they also killed MSLN-negative cells. In the mesothelioma model, MB-TRAIL M28z extended survival by 17 days over M28z (p=0.0249); in the A549 model median survival was day 105 versus day 73 (p=0.0002). In cultured A549 cells doxorubicin raised DR5 expression levels; in mice, doxorubicin (0.25 µg/g) did not improve overall survival in either treatment group, but combined with MB-TRAIL M28z CAR-T cells it reduced MSLN-positive liver metastasis. The authors concluded that their findings support developing MB-TRAIL-armoured CAR-T cells.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: preclinical study: in vitro co-culture killing assays with human CAR-T cells plus mouse xenograft therapy experiments with multiplexed bioluminescence imaging
• Who was studied: Human T cells from healthy volunteer buffy coats; MSTO-211H pleural mesothelioma and A549 NSCLC cell lines engineered as MSLN-positive and MSLN-negative; 72 NOD SCID gamma IL2rg−/− male mice, 5–6 weeks old, at Memorial Sloan Kettering Cancer Center
• Exposure: Mesothelin-directed second-generation M28z CAR-T cells, with or without membrane-bound TRAIL (ATF7-TRAIL-LZ chimera); comparison agents recombinant human TRAIL, doxorubicin (0.1, 0.25 or 0.5 µg/g in mice; 0.1 and 0.25 µg/mL in vitro) and bortezomib (5 nM and 30 nM)
• Main results:
  • In vitro at a 1:2 target-to-effector ratio, 24 hours after treatment, MB-TRAIL M28z CAR-T cells killed more MSLN-positive target cells than M28z CAR-T cells: 58.5% vs 22.13% (MSTO-211 cells, p=0.0019) and 41.15% vs 14.84% (A549 cells, p<0.0001)
  • M28z CAR-T cells did not kill MSLN-negative cells, while MB-TRAIL M28z CAR-T cells did (MSTO-211H at 24 hours p=0.0032; A549 at 24 hours p<0.0001)
  • In the MSTO-211H pleural mesothelioma model (controls N=8; M28z N=5; MB-TRAIL M28z N=9), MB-TRAIL M28z CAR-T cells suppressed MSLN-negative tumour growth (day 45: p=0.0005) and extended survival by 17 days over M28z (p=0.0249); untreated mice reached median survival on day 27 and M28z-treated mice died by day 46
  • In the A549 NSCLC model, MB-TRAIL M28z CAR-T cells extended median survival to day 105 versus day 73 for M28z CAR-T cells (p=0.0002); untreated tumour-bearing mice had a median survival of 45 days
  • In cultured A549 cells, doxorubicin raised DR5 expression levels dose-dependently, significant at 0.1 µg/mL in both MSLN-positive (p=0.0052) and MSLN-negative cells (p=0.0055)
  • In mice, doxorubicin (0.25 µg/g) did not improve overall survival in either treatment group, but its combination with MB-TRAIL M28z CAR-T cells markedly reduced MSLN-positive liver metastasis; MB-TRAIL M28z plus doxorubicin outlived M28z plus doxorubicin (median day 109 vs day 76, p<0.0001)
  • Intracellular IFN-gamma and TNF-alpha levels were comparable in MB-TRAIL M28z and unarmoured M28z CAR-T cells
• The authors' conclusion: The authors concluded that MB-TRAIL-armoring gave superior antitumour efficacy compared with clinically trialed M28z CAR-T cells by targeting heterogeneous antigen expression, and that their findings support developing this as a new class of CAR-T cell immunotherapies
• Limitations the authors state:
  • The authors stated the xenograft models do not fully reproduce the complexity of human tumours
  • No formal power calculation was done; group sizes were based on historical data and feasibility
  • Investigators were not blinded to treatment allocation
  • Spectral unmixing was not performed, so reporters had to be imaged sequentially with intervals to allow substrate clearance
  • The authors attributed the limited effect of doxorubicin in mice to suboptimal intratumoral drug exposure, a timing mismatch, heterogeneous DR5 expression and use of a single subtherapeutic dose

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer, Mesothelioma.

Medical terms in this study, explained in our Lexicon: CAR-T Cell, Mesothelin, Necrosis, Apoptosis, Pleural Mesothelioma, Lung Cancer, Doxorubicin.

Related studies

• Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity — Y. Yang, Y. Vedvyas, et al. (2024)
• Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study — T. Xu, T. Tian, et al. (2024)
• JNJ-79032421, a Novel Membrane-Restricted Mesothelin-Targeting T Cell-Engaging Bispecific Antibody for the Treatment of Mesothelin-Positive Cancers — K. Smans, T. Nesspor, et al. (2026)
• Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies — G.L. Beatty, A.R. Haas, et al. (2014)
• Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors — E. Hatterer, X. Chauchet, et al. (2020)
• Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer — J. Lv, R. Zhao, et al. (2019)

Browse more research in Journal for Immunotherapy of Cancer, or return to medical research.